Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

December 14, 2023

Opinion

Video

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

EP: 1.Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

EP: 2.Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Now Viewing

EP: 3.Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

EP: 4.KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

EP: 5.Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

EP: 6.Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

EP: 7.Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

EP: 8.Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

EP: 9.Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

EP: 10.Face-Off: Award Presentations and Event Conclusion

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!